MedTrace Logo

Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis

NCT05686447 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-04-06

No results posted yet for this study

Summary

To provide a comprehensive MALDI-TOF mass spectrometry method for detecting, characterizing, and quantifying M-protein, and to track M-protein in a very sensitive and specific manner during patient treatment, providing a more precise test for diagnosing disease and monitoring patient response to treatment.

Conditions

Interventions

OTHER

Observational studies, no intervention

Observational studies, no intervention

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Hongwei Zhou, Professor · Zhujiang Hospital

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2026-06-01
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686447 on ClinicalTrials.gov